Skip to main content
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. — Investor Relations & Filings

Ticker · HOWL ISIN · US95075A1079 US Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2023-01-10 Director's Dealing
Country US United States of America
Listing US HOWL

About Werewolf Therapeutics, Inc.

https://werewolftx.com/

Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-01-10 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-10 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-10 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing financial results for the quarter ended September 30, 2022, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length is 3793 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full earnings release or detailed financial data itself. Therefore, the appropriate classification is RNS with high confidence.
2022-11-10 English
8-K
Audit Report / Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 31, 2022, reporting a change in the company's independent registered public accounting firm from Deloitte & Touche LLP to Ernst & Young LLP. It details the dismissal of Deloitte, the appointment of Ernst & Young, and includes disclosures about audit opinions, disagreements, and reportable events related to the auditors. The document also references a letter from Deloitte attached as an exhibit. This type of filing is specifically about changes in the company's auditor and related audit information, which fits the definition of an Audit Report / Information filing (AR). The document is not a full annual report or financial statement but a standalone audit-related report. The length and content confirm it is not merely an announcement but a substantive report on auditor changes and audit matters.
2022-09-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.